LGD-3303

LGD-3303 is a drug which acts as a selective androgen receptor modulator (SARM), with good oral bioavailability. It is a selective agonist for the androgen receptor, producing functional selectivity with effective dissociation of anabolic and androgenic effects, acting as a partial agonist for androgenic effects, but a full agonist for anabolic effects.[1] It has been investigated as a possible treatment for osteoporosis, and was shown in animal studies to enhance the effectiveness of a bisphosphonate drug.[2]

LGD-3303
Clinical data
Routes of
administration		By mouth
Identifiers
IUPAC name
  • 9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H,6H,7H-pyrrolo[3,2-f]quinolin-7-one
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC16H14ClF3N2O
Molar mass342.75 g·mol−1
3D model (JSmol)
SMILES
  • CCC1=C(C2=C(N1CC(F)(F)F)C=CC3=C2C(=CC(=O)N3)Cl)C
InChI
  • InChI=1S/C16H14ClF3N2O/c1-3-11-8(2)14-12(22(11)7-16(18,19)20)5-4-10-15(14)9(17)6-13(23)21-10/h4-6H,3,7H2,1-2H3,(H,21,23)
  • Key:OMXGOGXEWUCLFI-UHFFFAOYSA-N
  (verify)

References
  1. Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, et al. (February 2009). "Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator". The Journal of Pharmacology and Experimental Therapeutics. 328 (2): 663–70. doi:10.1124/jpet.108.146811. PMID 19017848. S2CID 22107491.
  2. Vajda EG, Hogue A, Griffiths KN, Chang WY, Burnett K, Chen Y, et al. (February 2009). "Combination treatment with a selective androgen receptor modulator q(SARM) and a bisphosphonate has additive effects in osteopenic female rats". Journal of Bone and Mineral Research. 24 (2): 231–40. doi:10.1359/jbmr.081007. PMID 18847323. S2CID 21995180.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.